Clinical trials: Dose Administration Aids
HIV Infection
TMC114-C214: Trial of TMC114 Administered With Low Dose Ritonavir (RTV) in HIV-1 Infected Treatment Experienced Patients
Study TMC114-C214 is a randomized, controlled, open-label trial to compare the efficacy, safety and tolerability of TMC114 boosted with low dose ritonavir (RTV) versus Kaletra (LPV)/RTV in lopinavir-naïve treatment-experienced…
- Trial name
- NCT00110877
- Testing
- LPV/rtv, TMC114/rtv
- Where
- 103 sites in United States, Argentina and 24 more
- Volunteers
- 604 people
- Sponsor
- Tibotec Pharmaceuticals, Ireland
Human Immunodeficiency Virus (HIV)
Study to Evaluate the Safety and How the Body Handles a Single Dose of Subcutaneous (SC) and Intravenous (IV) Budigalimab in Adult Participants Living With Human Immunodeficiency Virus (HIV)
This study will evaluate how safe Budigalimab is and how it moves within the body in adult participants with HIV-1 infection. Budigalimab is an investigational drug being evaluated for the treatment of Human Immunodeficiency…
- Trial name
- NCT04799353
- Testing
- Budigalimab
- Where
- 10 sites in United States, Puerto Rico
- Volunteers
- 33 people
- Sponsor
- AbbVie
HIV Infections
A Trial of Two Doses of 2',3'-Dideoxycytidine (ddC) in the Treatment of Children With Symptomatic HIV Infection Who Are Intolerant of AZT and/or Who Show Progressive Disease While on AZT
To evaluate and compare the long-term (48-177 weeks) safety, tolerance, and efficacy of two doses of zalcitabine ( dideoxycytidine; ddC ) taken orally every 8 hours in children with symptomatic HIV infection who have one of the…
- Trial name
- NCT00000653
- Testing
- Zalcitabine
- Where
- 35 sites in United States, Puerto Rico
- Volunteers
- 140 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections, Peripheral Nervous System Diseases
Study of NGX-4010 for Treatment of Painful HIV-Associated Neuropathy
The purpose of the study is to determine if an investigational drug, NGX-4010 (high-concentration capsaicin patch), is safe, tolerable and effective in treating painful HIV-associated neuropathy.
- Conditions
- HIV Infections, Peripheral Nervous System Diseases, Pain
- Trial name
- NCT00085761
- Testing
- Capsaicin Dermal Patch
- Where
- 2 sites in United States
- Sponsor
- NeurogesX
Cytomegalovirus Retinitis, HIV Infections
A Study of Two Forms of Ganciclovir in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS
To compare the time to progression of Cytomegalovirus (CMV) retinitis among each of three doses of oral ganciclovir, as well as to intravenous therapy, when given as maintenance for 26 weeks.
- Trial name
- NCT00002330
- Testing
- Ganciclovir
- Where
- 36 sites in United States, Canada
- Volunteers
- 280 people
- Sponsor
- Roche Global Development
HIV Infections
Bioequivalency Study of Zidovudine Under Fed Conditions
The objective of this study was to assess the bioequivalence of Roxane's zidovudine 300 mg tablet compared to GlaxoSmithKline's Retrovir® 300 mg tablet under fed conditions using a single-dose, randomized, 2-treatment, 2-period…
- Trial name
- NCT00601562
- Testing
- Zidovudine
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
HIV Infections, Lipodystrophy
SHARE: Simple HAART With Abacavir, Reyataz, and Epivir
SHARE: Simple HAART with Abacavir, Reyataz, and Epivir
- Trial name
- NCT00426296
- Testing
- atazanavir (Reyataz), ritonavir (Norvir)
- Where
- United States
- Sponsor
- Clinical Alliance for Research & Education - Infectious Diseases, LLC.
HIV Infections
Drug Interaction Study Between Lumefantrine and Lopinavir/Ritonavir
With the roll out of antiretroviral therapy (ARV) for HIV across sub-Saharan Africa an unprecedented number of people will be commencing lifelong therapy.
- Trial name
- NCT00619944
- Testing
- Lumefantrine - lopinavir/ritonavir drug interaction, Lumefantrine only arm
- Where
- Uganda
- Volunteers
- 32 people
- Sponsor
- Makerere University
Human Immunodeficiency Virus
Single Ascending Dose (SAD)/Multiple Ascending Dose(MAD) Safety/Pharmacokinetic (PK) Study of KM-023
The purpose of this study is to investigate the safety and pharmacokinetics of KM-023 after single/multiple dosing.
- Trial name
- NCT01348516
- Testing
- KM-023
- Where
- South Korea
- Volunteers
- 83 people, healthy volunteers welcome
- Sponsor
- Kainos Medicine Inc.
Malaria, Falciparum, HIV Infections
Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi
In Malawi, the standard of care to prevent malaria during pregnancy at the time of the study was a two dose sulfadoxine-pyrimethamine intermittent protective treatment (SP IPT) regimen administered in the second and third…
- Trial name
- NCT00126906
- Testing
- Monthly sulfadoxine/pyrimethamine, 2-dose sulfadoxine/pyrimethamine
- Where
- Malawi
- Volunteers
- 700 people
- Sponsor
- Centers for Disease Control and Prevention
Hepatitis C, Medication Adherence
Intensive Models of HCV Care for Injection Drug Users
Injection drug users (IDUs) constitute 60% of the approximately 5 million people in the U.S. infected with hepatitis C virus (HCV). HCV treatment leading to sustained viral response (SVR) is associated with increased survival.
- Trial name
- NCT01857245
- Testing
- Intensive Models (mDOT and CGT) of HCV Care
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Prisma Health-Upstate
Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS), Human Immunodeficiency Virus Infections
Safety and Efficacy Trial of Serostim® in the Treatment of Subjects With Human Immunodeficiency Virus-associated Adipose Redistribution Syndrome (HARS)
This study is a Phase 2/3, multicenter, double-blind, randomized, parallel-group, placebo-controlled, dose-finding trial of Serostim® (mammalian cell-derived recombinant human growth hormone, r-hGH) versus placebo in subjects…
- Trial name
- NCT00294164
- Testing
- Serostim®
- Volunteers
- 245 people
- Sponsor
- EMD Serono
HIV-1 Infection
SONETT: Switch Study to Once Daily HIV Treatment Regimen With Truvada
There is an unmet medical need for potent ART regimens that make adherence to treatment even easier due to QD dosing, offer a good tolerability profile and fit into the daily life of patients.
- Trial name
- NCT00323687
- Testing
- Truvada
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Gilead Sciences
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Trimetrexate in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS Not Previously Treated for PCP
To evaluate the safety and effectiveness of trimetrexate (TMTX) given at increasing doses along with the leucovorin calcium (LCV) for treating Pneumocystis carinii pneumonia (PCP) in AIDS patients TMTX is an experimental new drug…
- Trial name
- NCT00000998
- Testing
- Trimetrexate glucuronate, Leucovorin calcium
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Cytomegalovirus Retinitis, HIV Infections
A Study of ISIS 2922 in the Treatment of Advanced Cytomegalovirus Retinitis
The purpose of this study is to compare the safety and effectiveness of two dosage schedules for ISIS 2922 in the treatment of advanced cytomegalovirus (CMV) retinitis
- Trial name
- NCT00002187
- Testing
- Fomivirsen sodium
- Where
- 17 sites in United States
- Sponsor
- Ionis Pharmaceuticals, Inc.
HIV Infections
A Post Marketing Surveillance Study Assessing the Long-term Efficacy and Safety of Aptivus Co-administered With Low-dose Ritonavir in Treatment Experienced Patients With HIV-1 Infection in the Daily Clinical Practice.
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Aptivus in treatment-experienced patients with advanced HIV-1 infection who had developed resistance to more than one protease…
- Trial name
- NCT00976950
- Testing
- Tipranavir, ritonavir
- Where
- 20 sites in Romania
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
HIV Infection, HIV Infections
Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients
The licensed dose of raltegravir is 400 mg twice daily with or without food. Raltegravir is metabolized predominantly through glucuronidation by UGT1A1.
- Trial name
- PRADA (NCT00943540)
- Testing
- raltegravir QD, atazanavir, lamivudine (or emtricitabine)
- Where
- 4 sites in Germany, Netherlands
- Volunteers
- 20 people
- Sponsor
- Radboud University Medical Center
Cytomegalovirus Retinitis, HIV Infections
A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure
To examine the usefulness and safety of the antiviral drug foscarnet in treating AIDS patients with cytomegalovirus (CMV) infection that is causing sight-threatening inflammation of the retina in one or both eyes (CMV retinitis).
- Trial name
- NCT00000691
- Testing
- Foscarnet sodium
- Where
- 11 sites in United States
- Volunteers
- 156 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV, Tuberculosis
Tuberculosis and Human Immunodeficiency Virus (HIV) Immune Reconstitution Syndrome Trial (THIRST)
The purpose of this study is twofold: (1) to assess the feasibility and safety of fixed dose combination zidovudine/lamivudine/abacavir in HIV infected subjects with tuberculosis in a resource-limited setting, and (2) to assess…
- Trial name
- THIRST (NCT00851630)
- Testing
- Fixed dose combination zidovudine/lamivudine/abacavir
- Where
- Tanzania
- Volunteers
- 70 people
- Sponsor
- Duke University
Infection, Human Immunodeficiency Virus, HIV Infections
Safety and Efficacy Study of GSK2838232 in Human Immunodeficiency Virus (HIV)-1 Infected Adults
GSK2838232 is a novel HIV-1 maturation inhibitor (MI) that is being developed for the treatment of HIV-1 infection in combination with other antiretroviral therapy (ART).
- Trial name
- NCT03045861
- Testing
- GSK2838232, Cobicistat
- Where
- 14 sites in United States, Canada
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline